Entera Bio Ltd.
ENTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -48.8% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | 0% | 0% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -6,083.3% | -2,836.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -6,111.9% | -2,875.6% |
| EPS Diluted | 0.07 | -0.057 | 0.06 | -0.063 |
| % Growth | 223.5% | -194.5% | 195.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |